These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30056574)

  • 1. Artemisinins-a Promising New Treatment for Systemic Lupus Erythematosus: a Descriptive Review.
    Mu X; Wang C
    Curr Rheumatol Rep; 2018 Jul; 20(9):55. PubMed ID: 30056574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artemisinin analogue SM934 protects against lupus-associated antiphospholipid syndrome via activation of Nrf2 and its targets.
    Lin Z; Liu Y; Chen L; Cao S; Huang Y; Yang X; Zhu F; Tang W; He S; Zuo J
    Sci China Life Sci; 2021 Oct; 64(10):1702-1719. PubMed ID: 33481164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway.
    Dang WZ; Li H; Jiang B; Nandakumar KS; Liu KF; Liu LX; Yu XC; Tan HJ; Zhou C
    Phytomedicine; 2019 Sep; 62():152965. PubMed ID: 31129432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prednisone combined with Dihydroartemisinin attenuates systemic lupus erythematosus by regulating M1/M2 balance through the MAPK signaling pathway.
    Chen Y; Tao T; Liang Z; Chen X; Xu Y; Zhang T; Zhou D
    Mol Immunol; 2024 Jun; 170():144-155. PubMed ID: 38669759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.
    Yap DYH; Chan TM
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
    Staveri C; Karokis D; Liossis SC
    Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune suppressive properties of artemisinin family drugs.
    Hou L; Huang H
    Pharmacol Ther; 2016 Oct; 166():123-7. PubMed ID: 27411673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of systemic lupus erythematosus: myths, certainties and doubts].
    Ruiz-Irastorza G; Danza A; Khamashta M
    Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory and immunoregulatory functions of artemisinin and its derivatives.
    Shi C; Li H; Yang Y; Hou L
    Mediators Inflamm; 2015; 2015():435713. PubMed ID: 25960615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses.
    Hou LF; He SJ; Li X; Yang Y; He PL; Zhou Y; Zhu FH; Yang YF; Li Y; Tang W; Zuo JP
    Arthritis Rheum; 2011 Aug; 63(8):2445-55. PubMed ID: 21484768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation.
    Wu Y; He S; Bai B; Zhang L; Xue L; Lin Z; Yang X; Zhu F; He P; Tang W; Zuo J
    Cell Mol Immunol; 2016 May; 13(3):379-90. PubMed ID: 25942599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review.
    Yoon KH
    J Biomed Biotechnol; 2010; 2010():686480. PubMed ID: 20625508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-17 in systemic lupus erythematosus: A comprehensive review.
    Li D; Guo B; Wu H; Tan L; Chang C; Lu Q
    Autoimmunity; 2015; 48(6):353-61. PubMed ID: 25894789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus.
    Feng X; Chen W; Xiao L; Gu F; Huang J; Tsao BP; Sun L
    Lupus; 2017 Jan; 26(1):62-72. PubMed ID: 27230555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel and emerging drugs for systemic lupus erythematosus: mechanism of action and therapeutic activity.
    Robak E; Robak T
    Curr Med Chem; 2012; 19(3):438-53. PubMed ID: 22335517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Protective Arm of the Renin-Angiotensin System to Reduce Systemic Lupus Erythematosus Related Pathologies in MRL
    Soto M; Delatorre N; Hurst C; Rodgers KE
    Front Immunol; 2020; 11():1572. PubMed ID: 32793221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural products action on pathogenic cues in autoimmunity: Efficacy in systemic lupus erythematosus and rheumatoid arthritis as compared to classical treatments.
    Cao F; Cheng MH; Hu LQ; Shen HH; Tao JH; Li XM; Pan HF; Gao J
    Pharmacol Res; 2020 Oct; 160():105054. PubMed ID: 32645358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune Responses and Therapeutic Interventions for Systemic Lupus Erythematosus: A Comprehensive Review.
    Pandey SP; Bhaskar R; Han SS; Narayanan KB
    Endocr Metab Immune Disord Drug Targets; 2024; 24(5):499-518. PubMed ID: 37718519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H; Li T; Chen S; Gu Y; Ye S
    Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New biologic therapy for systemic lupus erythematosus.
    Ding HJ; Gordon C
    Curr Opin Pharmacol; 2013 Jun; 13(3):405-12. PubMed ID: 23664092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.